† A COVID-19 case in a fully vaccinated person occurred when SARS-CoV-2 RNA or antigen was detected in a respiratory specimen collected ≥14 days after completing the primary series of a COVID-19 vaccine with Food and Drug Administration (FDA) approval or emergency use authorization. The COVID-19 case definition, including criteria to distinguish a new case from an existing case, is per the July 2021 update to the national standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19) (21-ID-01) (https://ndc.services.cdc.gov/case-definitions/ coronavirus-disease-2019-2021/). Fully vaccinated persons were those with a completed primary series of 2 doses of the Pfizer-BioNTech or Moderna mRNA vaccine or a single dose of the Janssen vaccine (https://www.cdc.gov/ coronavirus/2019-ncov/vaccines/stay-up-to-date.html). A COVID-19 case in an unvaccinated person occurred when the person did not receive any FDAauthorized COVID-19 vaccine doses before the specimen collection date. Cases were excluded in partially vaccinated persons who received at least one FDAauthorized or approved vaccine dose but did not complete a primary series ≥14 days before collection of a respiratory specimen with SARS-CoV-2 RNA or antigen detected. Ascertaining vaccination status for COVID-19 patients through active linkage of case surveillance and immunization information systems typically assumes that cases among persons who are unmatched to the registry are unvaccinated. This analysis represents the combined impact of the Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines, which had different clinical efficacies against confirmed infection. Information on different FDA-authorized and approved COVID-19 vaccine products, including clinical efficacy, is available online. https://www.cdc.gov/coronavirus/2019-ncov/ vaccines/different-vaccines.html

No abstract

No abstract

This article examines Covid-19 case and death rates among recipients of one of three FDA-approved vaccines. The data show that protection from infection attributable to the BNT162b2 and mRNA-1273 vaccine recipients and from death among older BNT162b2 recipients wanes over 6 months, whereas case and death rates among recipients of the Ad26.COV2.S vaccine are higher overall without a consistent pattern of waning immunity.

This article examines Covid-19 case and death rates among recipients of one of three FDA-approved vaccines. The data show that protection from infection attributable to the BNT162b2 and mRNA-1273 vaccine recipients and from death among older BNT162b2 recipients wanes over 6 months, whereas case and death rates among recipients of the Ad26.COV2.S vaccine are higher overall without a consistent pattern of waning immunity.